AJU IB Investment

AJU IB Investment is a prominent South Korean venture capital and private equity firm, established in 1974 as the nation's first venture capital company. The firm has a long-standing track record of supporting innovative companies across various stages of their lifecycle, from early-stage startups to pre-IPO and post-IPO phases. With a cumulative managed fund exceeding KRW 3.2 trillion over the past two decades, AJU IB Investment demonstrates both stability and profitability, having successfully liquidated 38 funds. They are also pioneers in South Korea for endorsing the TCFD and adopting an ESG investment approach since 2021, emphasizing a sustainable venture ecosystem.

The firm's investment strategy is multi-faceted, encompassing venture capital and private equity investments. While AJU IB Investment broadly targets sectors such as healthcare, technology, information technology (including mobile service platforms, software, semiconductors, and AI), biotechnology, life science, and environment sectors, its U.S. subsidiary, Solasta Ventures, has a more specialized focus. Solasta Ventures, incorporated in 2019 from AJU IB Investment's Americas office established in 2013, primarily invests in pharmaceutical and biotech startups from its Boston headquarters, with a Silicon Valley branch focusing on AI, cloud, big data, robotics, and autonomous driving.

AJU IB Investment and its subsidiary Solasta Ventures actively seek to invest in companies that advance the standard of care for diseases with unmet medical needs, leveraging deep scientific expertise and an extensive network. Their portfolio includes investments in therapeutics, drug development, cell therapy, and genetic medicines, with a particular interest in oncology, neurology, and immunology. Solasta Ventures has shown impressive investment results, with 19 of its 38 invested companies being listed on NASDAQ by June 2023, acting as a crucial bridge between American startups and Korean companies.

The leadership team includes Jiwon Kim as the CEO of AJU IB Investment, overseeing the firm's comprehensive investment strategies. Derek Yoon serves as the President & CEO of Solasta Ventures, leading its U.S. investments with a focus on life science companies and early-stage startups with novel science. The team's collective experience in healthcare investments and drug development, coupled with a scientific advisory board, underpins their ability to identify and nurture promising ventures globally.